The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

Lymphangioleiomyomatosis (LAM)

Rare progressive cystic lung disease almost exclusively in women, characterized by abnormal smooth muscle proliferation along bronchi, vessels, and lymphatics, leading to diffuse lung cysts and respiratory failure.

Written by: Saygı Hospital Health Guide Editorial Board
Last updated:

This content has been compiled by the Saygı Hospital Health Guide Editorial Board and is periodically reviewed by a specialist physician.

References (5)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göğüs Hastalıkları department. Book Appointment →

What is Lymphangioleiomyomatosis (LAM)?

LAM cells harbor TSC1 or TSC2 mutations leading to mTOR pathway hyperactivation, abnormal cell proliferation, and metalloproteinase-mediated tissue destruction. The relationship to estrogen is strong: disease onset in reproductive age, exacerbation with pregnancy and exogenous estrogens, expression of estrogen and progesterone receptors on LAM cells.

Pulmonary pathology: diffuse, bilateral, thin-walled cysts (2-30 mm) replace normal lung parenchyma; LAM cell foci surround vessels, airways, and lymphatics; smooth muscle proliferation causes airflow obstruction and air trapping; cyst rupture leads to pneumothorax; lymphatic obstruction causes chylothorax.

Extrapulmonary: renal angiomyolipomas (benign tumors with risk of hemorrhage at >4 cm), retroperitoneal/abdominal lymphangioleiomyomas (cystic lymphatic masses), chylous ascites, hepatic involvement. TSC association: 30-40% of women with TSC have LAM (subclinical to severe).

Symptoms

Progressive dyspnea on exertion (initial symptom)
Spontaneous pneumothorax (50-80%, often recurrent)
Chylous pleural effusion (20-30%, milky white, lymphatic origin)
Hemoptysis (uncommon)
Cough, chest pain
Abdominal pain or palpable mass (renal angiomyolipoma, chylous ascites)
Tuberous sclerosis features (skin findings, seizures, intellectual disability) in TSC-LAM
Severe disease: respiratory failure, cor pulmonale

Risk Factors

Female sex (>99% of cases)
Reproductive age (mean diagnosis 35-45 years, range 18-65)
Tuberous sclerosis complex (TSC1 or TSC2 mutations)
Estrogen exposure (oral contraceptives may worsen, pregnancy may exacerbate)
Smoking history (controversial — does not cause LAM but may worsen)
Family history (only in TSC-LAM)

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • Spontaneous pneumothorax in young woman
  • Progressive dyspnea with characteristic CT cysts
  • Recurrent pneumothorax
  • Chylothorax of unclear etiology
  • Renal angiomyolipoma in woman with respiratory symptoms
  • Pulmonology and TSC center referral for evaluation

Treatment Methods

01
Diagnostic workup: HRCT chest (diffuse round thin-walled cysts), serum VEGF-D >800 pg/mL (highly specific for LAM), abdominal CT/MRI for angiomyolipomas and lymphangioleiomyomas, pulmonary function tests (obstructive pattern, reduced DLCO), chylothorax analysis (lymphatic origin)
02
Diagnostic confirmation: characteristic CT + VEGF-D >800 OR characteristic CT + biopsy (lung, kidney, lymph node) showing LAM cells (HMB-45+, smooth muscle actin+, estrogen receptor+); TSC genetic testing if features
03
Sirolimus (rapamycin, mTOR inhibitor) — disease-modifying therapy: oral 1-2 mg daily, target trough 5-15 ng/mL; MILES trial demonstrated stabilization of FEV1 decline; reduces VEGF-D, angiomyolipoma size, lymphangioleiomyoma volume; FDA-approved 2015
04
Sirolimus indications: moderate-to-severe lung disease (FEV1 <70% predicted), problematic chylothorax/chylous ascites, large renal angiomyolipomas (>4 cm)
05
Sirolimus monitoring and adverse events: oral ulcers, diarrhea, acne-like rash, hyperlipidemia, cytopenias, infections; pregnancy contraindication; everolimus alternative in some cases
06
Pneumothorax management: 50-80% recurrence rate without intervention; first pneumothorax — chest tube; recurrent or large — pleurodesis (mechanical, talc, or surgical with apical pleurectomy); avoid pleurectomy in lung transplant candidates
07
Chylothorax management: dietary modifications (low-fat with medium-chain triglycerides), drainage, sirolimus often dramatic effect, pleurodesis or thoracic duct ligation in refractory cases
08
Renal angiomyolipoma management: surveillance for AML <4 cm; sirolimus (everolimus FDA-approved for TSC AML); selective embolization or partial nephrectomy for large symptomatic AML; AML rupture is medical emergency
09
Avoid estrogen-containing medications (oral contraceptives, hormone replacement) — may exacerbate disease
10
Pregnancy counseling: increased risk of disease progression and pneumothorax; not absolute contraindication but requires careful planning and pulmonary function monitoring
11
Lung transplantation: end-stage disease (FEV1 <30%, severe pulmonary hypertension, recurrent uncontrolled pneumothorax/chylothorax); LAM has good post-transplant outcomes; recurrence in transplanted lung described
12
Multidisciplinary care: LAM specialty centers, pulmonology, gynecology, nephrology, transplant team
13
Long-term: with sirolimus, FEV1 decline rate is reduced from ~75 mL/year to near zero; survival improved; ongoing surveillance with annual PFTs, abdominal imaging, TSC manifestations if applicable

Which Department to Visit?

You can visit our Göğüs Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Göğüs Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Asthma

Göğüs Hastalıkları

Asthma is characterized by wheezing, coughing and shortness of breath attacks; with proper treatment it can be kept under control.

COPD (Chronic Obstructive Pulmonary Disease)

Göğüs Hastalıkları

COPD is an irreversible lung disease characterized by shortness of breath and chronic cough; quitting smoking slows its progression.

Pneumonia

Göğüs Hastalıkları

Pneumonia presents with high fever, cough and shortness of breath; the vast majority recover with appropriate antibiotic treatment.

Tuberculosis (TB)

Göğüs Hastalıkları

Tuberculosis presents with weeks-to-months of cough, fever, and night sweats; early diagnosis and treatment lead to full recovery.

Pleural Effusion

Göğüs Hastalıkları

Pleural effusion is the accumulation of excess fluid in the pleural space, resulting from imbalances in fluid production and removal, and represents a manifestation of diverse cardiopulmonary, infectious, and malignant disorders.

Pneumothorax

Göğüs Hastalıkları

Pneumothorax is the presence of air in the pleural space resulting in partial or complete lung collapse, classified as spontaneous (primary/secondary), traumatic, or iatrogenic, with tension pneumothorax representing a life-threatening emergency.

Bronchitis (Acute and Chronic)

Göğüs Hastalıkları

Acute bronchitis is mostly viral and resolves spontaneously, while chronic bronchitis is a smoking-related component of COPD.

Bronchiectasis

Göğüs Hastalıkları

Bronchiectasis is a chronic respiratory disease characterized by permanent, abnormal dilation of bronchi with associated destruction of muscular and elastic components of airway walls, resulting in impaired mucociliary clearance and recurrent infection.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.